Financial News Archive

SEC EDGAR · Federal Reserve · FDA · BLS · Updated every 60s

Willdan
Willdan Energy to acquire Mantis Newco

Willdan Energy Solutions has entered into a definitive membership interest purchase agreement to acquire the assets of Mantis Newco, LLC....

ONE
ONE Nuclear Energy Inc. Closes Merger With Hennessy VII

The energy company completed a business combination, renamed itself ONE Nuclear Energy Inc., and will list its shares under the ticker symbol ONEN on ...

FIFTH
Fifth Third Bancorp Completes Exchange of Unregistered Notes

Fifth Third Bancorp has successfully completed a registered exchange offer for its outstanding unregistered senior notes, with over 99% of eligible de...

FMC
FMC agrees to investor agreement with Tessenderlo

FMC Corp enters into an investor agreement with Tessenderlo Group NV dated September 23, 2026, regarding a prior purchase of over 30 million shares....

RAYMOND
Raymond James Financial reports Record AUM of $1.97T

Client assets under administration grew 16% year-over-year driven by strong equity markets and net inflows, while bank loans and cash sweep balances a...

Bath
Bath & Body Works awards PSUs

The company granted 591,366 performance share units to Daniel Heaf with a target number of shares. The vesting is contingent upon simple stock price h...

Teamshares
Teamshares authorizes $300M of preferred stock

The company filed an amendment to its certificate of incorporation authorizing the issuance of up to $300 million of Series A preferred stock....

CLARIVATE
Clarivate prices tender of senior secured notes

Clarivate announced terms for the cash tender offer for its 3.875% Senior Secured Notes due 2028, with a price of $975.15. The action is a strategic m...

Theravance
Theravance Biopharma amends its bylaws.

Theravance Biopharma, Inc. adopted an amended and restated Memorandum and Articles of Association under the Cayman Islands Companies Act effective Sep...

Solaris
Solaris sells $1.25B senior notes

Solaris Energy Infrastructure proposes to issue and sell $1.25 billion principal amount of 7.000% senior notes due 2032. Market relevance: Proxy for t...

Orange
Orange County Bancorp reports Q2 2026 results

Orange County Bancorp, Inc. reported results for the second quarter of 2026. The filing includes an investor presentation detailing the company's fina...

NeoVolta
NeoVolta FY26 revenue up 58% to $13.3M; cash burns rise.

NeoVolta reported 58% YoY revenue growth to $13.3 million in FY26 but faced a net loss of $21.5 million as it transitions to a manufacturing platform....

Jazz
Jazz extends amendment on senior secured credit

Jazz Pharmaceuticals amended its senior secured credit agreement by Amendment No. 4, effective September 23, 2026. This corporate action maintains fin...

Leader's
Leader's Advantage Acquisition Corp. sells 15M units at $10.00 for IPO

The company agreed to issue and sell 15M units to underwriters for $9.40 net, priced at $10.00 each, pursuant to the Underwriting Agreement....

Arcturus
Arcturus Announces FDA Clears LEAP Technologies Platform

Arcturus confirms receipt of FDA clearance for its LEAP mRNA platform technology. This regulatory milestone underpins the development of its COVID-19 ...

Ready
RC amends indenture for 7.375% Senior Notes

Ready Capital Corp had consents to amend the indenture governing its 7.375% Senior Notes due 2027, as authorized by the Eighth Supplemental Indenture....

VSEE
Amendment incorporates reverse stock split effective Sept. 23, 2026

VSee Health filed an amendment to its charter to implement an 80-for-1 reverse stock split....

Zymeworks
Zymeworks sued for failing to pay contingent value rights (CVRs)

Zymeworks Inc. is being sued by acquisition target Theravance Biopharma after failing to pay out agreed-upon contingent value rights to shareholders f...

MARIMED
MariMed Files Definitive Proxy for Special Meeting to Approve Reverse Stock Split

MariMed Inc. filed a proxy statement for a special meeting seeking approval to implement a reverse stock split at the Board's discretion, aiming to ac...

Longeveron
Laromestrocel fails primary endpoint in HLHS trial

The ELPIS II trial failed to meet its primary efficacy endpoint but showed improved transplant-free survival and fewer cardiovascular events. Longever...